drugset / Trial / NCT05344365

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

NCT05344365

Phase 2 Withdrawn Vanda Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).

Timeline

Start
2022-06
Primary completion
2023-11
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule Oral

Indications